Technology Assessment Reports (TARs)

Technology Assessment Reports are detailed analyses of new medicines or medical devices. They are used to determine how cost-effective a product is.

We don't publish most of our Technology Assessment Reports (TARs) because of commercial sensitivity. We do release some reports with the commercial information removed.

TARs inform our prioritisation process

Published Pharmac Technology Assessment Reports

Trikafta (elexacaftor, tezacaftor and ivacaftor) for cystic fibrosis

Summary of Trikafta TAR

Download full Trikafta TAR [PDF, 951 KB]

Freestyle Libre flash glucose monitoring system

TAR 417 Economic analysis on the Freestyle Libre flash glucose monitoring system for type 1 diabetes [PDF, 2.2 MB]

Ivacaftor (Kalydeco) for cystic fibrosis with the G551D mutation 

TAR 400 Ivacaftor for cystic fibrosis with the G551D mutation [PDF, 1.3 MB]

Supplementary material for TAR 400 [PDF, 447 KB]

Funded: Ivacaftor in the Pharmaceutical Schedule(external link)

SGLT 2 inhibitors (modelled as empagliflozin)

TAR 382 SGLT 2 inhibitors for type 2 diabetes(external link)

Funded: SGLT 2 inhibitors in the Pharmaceutical Schedule(external link)

Ustekinumab (Stelara)

TAR 372 ustkinumab for severe crohn's disease [PDF, 4.8 MB]

Eculizumab (Soliris)

TAR 209 Preliminary economic analysis on eculizumab for paroxysmal nocturnal haemoglobinuria (PNH) May 2013 [PDF, 807 KB]

Nusinersen (Spinraza)

TAR 398 Nusinersen for Spinal Muscular Atrophy February 2020 [PDF, 7.4 MB]

Trastuzumab (Herceptin)

TAR 75a,b Trastuzumab (Herceptin) in HER-2 positive early breast cancer with 9 week regimen CUA [PDF, 566 KB]

TAR 75c Trastuzumab further sensitivity analysis [PDF, 401 KB]

Funded: Trastuzumab in the Pharmaceutical Schedule(external link)

Pembrolizumab (Keytruda)

TAR 271a and 271b Pembrolizumab in advanced melanoma [PDF, 7 MB]

Funded: Pembrolizumab in the Pharmaceutical Schedule(external link)